Monopar Therapeutics Reports P-III (FoCus) Trial Data on ALXN1840 in Wilson Disease

Shots: Monopar has highlighted P-III (FoCus) trial data assessing ALXN1840 (tiomolibdate choline, TMC; n=77) vs SoC (n=35) in Wilson disease pts with neurologic symptoms at baseline, at AAN’26 Trial showed better outcomes with ALXN1840, with lower neurologic worsening (9% vs 25%) & higher improvement (45% vs 32%) vs SoC, plus greater CGI-S (61% vs 17%)…

ByRidhi RastogiApril 21, 2026

NEWS

Akeso Announces P-II (COMPASSION-26) Trial Results on Cadonilimab + CT in 1L PDAC

Shots: Akeso has reported the P-II (COMPASSION-26) trial results assessing cadonilimab + CT as the 1L treatment of advanced pancreatic ductal adenocarcinoma (PDAC) As of Oct 20, 2025 (mFU of >2yrs.), trial showed robust & durable survival benefits, with mPFS of 11.1mos. & mOS of >23mos., showing 12 & 24mos. OS rate of 91.7% &…

ByRidhi RastogiApril 21, 2026

NEWS Uncategorized

Pheast Therapeutics Reports Early P-Ia Data for PHST001 at AACR 2026

Shots: Pheast Therapeutics presented initial P-Ia data for PHST001 at AACR Annual Meeting 2026, demonstrating target engagement, innate immune activation, and early clinical activity PHST001 (anti-CD24 macrophage checkpoint inhibitor) was generally well tolerated, across dose-escalation cohorts and early signals of clinical activity were observed incl. tumor shrinkage and disease stabilization Preclinical data showed enhanced tumor…

ByPrince GiriApril 20, 2026

NEWS

Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease

Shots: Novo Nordisk reported that etavopivat met both co-1EPs in the P-III (HIBISCUS) study, reducing vaso-occlusive crises (VOCs) and improving haemoglobin response in sickle cell disease The study (n=385, ≥12yrs) evaluated Etavopivat (400mg) vs PBO demonstarting reduced VOCs rates by 27% and delayed time to first VOC (~38.4 vs 20.9 weeks), while 48.7% of patients…

ByPrince GiriApril 20, 2026

NEWS

AstraZeneca Reports Positive P-III (MIRANDA) Data for Tozorakimab in COPD

Shots: AstraZeneca announced that tozorakimab met the 1EP in the P-III (MIRANDA) study, significantly reducing annualised rate of moderate-to-severe COPD exacerbations across pts. with COPD that still experiencing exacerbations while on inhaled SoC In study pts. (n=1,454) received tozorakimab 300mg or PBO on top of SoC once every two weeks, including former and current smokers,…

ByPrince GiriApril 20, 2026

NEWS

EpiBiologics Reports First Patient Dosed in P-I Study of EPI-326 for EGFR-Driven Solid Tumors

Shots: EpiBiologics has dosed the first patient in a global P-I study evaluating EPI-326, a tissue-selective bispecific antibody targeting EGFR, in advanced solid tumors The first-in-human study will assess safety, tolerability, PK, and preliminary anti-tumor activity in pts with NSCLC and HNSCC, with potential expansion into colorectal cancer Preclinical data showed robust anti-tumor activity across…

ByPrince GiriApril 20, 2026

NEWS

Eli Lilly Reports Positive P-III (ACHIEVE-4) Data of Foundayo in Type 2 Diabetes and Obesity or Overweight

Shots: Eli Lilly reported positive topline results from the P-III (ACHIEVE-4) study of Foundayo (orforglipron) vs insulin glargine in ~2,700 pts with type 2 diabetes, and obesity or overweight with elevated CV risk, meeting the 1EP of non-inferiority in MACE-4 events Foundayo demonstrated a 16% lower risk of MACE-4 and 23% lower risk of MACE-3,…

ByPrince GiriApril 17, 2026

NEWS

Radiopharm Completes Final Patient Dosing of RAD 101 for Diagnosis of Brain Metastases in the US

Shots: Radiopharm Theranostics has reported that the final patient has been dosed in its US P-IIb imaging trial of RAD 101, evaluating recurrent brain metastases in patients with solid tumors. 1EP readout is expected in Jun’26, with plans to advance RAD 101 into a US P-III pivotal trial The P-IIb trial is assessing 18F-RAD101 in…

ByDipanshu DixitApril 17, 2026

NEWS

SynOx Therapeutics Reports Topline P-III (TANGENT) Trial Results on Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Shots: SynOx has reported the global P-III (TANGENT) trial data assessing emactuzumab (1000 mg Q2W × 5 doses over 8wks.) vs PBO in TGCT for 6mos., followed by 18mos. follow-up with option for open-label emactuzumab upon disease progression Trial met 1 & 2EPs with high significance, improving ORR (RECIST v1.1) & Tumor Volume Score, along…

ByRidhi RastogiApril 14, 2026

NEWS

Eli Lilly Reports P-III (BRUIN CLL-322) Trial Data on Jaypirca Combination for CLL/SLL

Shots: The P-III (BRUIN CLL-322) trial assessed Jaypirca + venetoclax & rituximab vs venetoclax & rituximab in r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), with both arms treated ~2yrs. followed by therapy-free period until disease progression The trial met its 1EP, demonstrating improved PFS per IRC, with consistent results across clinically relevant subgroups…

ByRidhi RastogiApril 14, 2026

Monopar Therapeutics Reports P-III (FoCus) Trial Data on ALXN1840 in Wilson Disease

Akeso Announces P-II (COMPASSION-26) Trial Results on Cadonilimab + CT in 1L PDAC

Pheast Therapeutics Reports Early P-Ia Data for PHST001 at AACR 2026

Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease

AstraZeneca Reports Positive P-III (MIRANDA) Data for Tozorakimab in COPD

EpiBiologics Reports First Patient Dosed in P-I Study of EPI-326 for EGFR-Driven Solid Tumors

Eli Lilly Reports Positive P-III (ACHIEVE-4) Data of Foundayo in Type 2 Diabetes and Obesity or Overweight

Radiopharm Completes Final Patient Dosing of RAD 101 for Diagnosis of Brain Metastases in the US

SynOx Therapeutics Reports Topline P-III (TANGENT) Trial Results on Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Eli Lilly Reports P-III (BRUIN CLL-322) Trial Data on Jaypirca Combination for CLL/SLL

Contact US

FOLLOW US